2018
Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Drugs T, Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo A, Koumare S, Keita M, Camara D, Somé A, Coulibaly A, Traore O, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini M, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore M, Ouattara S, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma E, Thera I, Compaore Y, Sutherland C, Sylla M, Nikiema F, Diallo M, Dicko A, Picot S, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Gil J, Björkman A, Ouedraogo J, Sirima S, Djimde A. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet 2018, 391: 1378-1390. PMID: 29606364, PMCID: PMC5889791, DOI: 10.1016/s0140-6736(18)30291-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyFirst-line artemisinin-based combination therapyArtemether-lumefantrineDay 28Day 42Study drugUncomplicated malariaMalaria episodesEligible participantsIncidence ratePan African Clinical Trials RegistryUncomplicated P falciparum malariaCurrent first-line therapyAfrican Clinical Trials RegistryDeveloping Countries Clinical Trials PartnershipDihydroartemisinin-piperaquine treatmentFirst malaria episodeP falciparum malariaUncomplicated malaria episodesFirst-line therapyHistory of feverClinical Trials RegistryNon-falciparum speciesMild transient elevationUK Medical Research Council
2016
Factors Affecting the Validity of Coverage Survey Reports of Receipt of Vitamin A Supplements During Child Health Days in Southwestern Burkina Faso
Ouédraogo C, Becquey E, Wilson S, Prince L, Ouédraogo A, Rouamba N, Ouédraogo J, Vosti S, Brown K, Hess S. Factors Affecting the Validity of Coverage Survey Reports of Receipt of Vitamin A Supplements During Child Health Days in Southwestern Burkina Faso. Food And Nutrition Bulletin 2016, 37: 529-543. PMID: 27604622, DOI: 10.1177/0379572116666167.Peer-Reviewed Original ResearchConceptsOral polio vaccineOdds ratioChildren 6High-dose vitaminVitamin A supplementsCross-sectional studyLongitudinal studyMonths old childrenCaregivers of childrenChild Health DaysMonths of ageCross-sectional surveyFalse positive reportingSupplementation coverageVAS coverageFalse positive reportsA supplementsOral vaccinePolio vaccineCoverage surveyHealth daysOlder childrenVASMonthsWeeks
1994
Ten-year surveillance of drug-resistant malaria in Burkina Faso (1982-1991).
Guiguemde T, Aouba A, Ouedraogo J, Lamizana L. Ten-year surveillance of drug-resistant malaria in Burkina Faso (1982-1991). American Journal Of Tropical Medicine And Hygiene 1994, 50: 699-704. PMID: 8024062, DOI: 10.4269/ajtmh.1994.50.699.Peer-Reviewed Original ResearchConceptsTen-year surveillanceBobo-DioulassoDrug-resistant malariaDrug-resistant formsPrevalence of resistanceFirst caseChloroquine sensitivityVivo resistanceCases of resistanceMalaria transmissionBurkina FasoPlasmodium falciparumMefloquineHigh rateMalariaPyrimethamineChloroquineVitroVivoActive surveyLevel of resistancePrevalence